Ajulemic acid_product_DataBase

Bioactivity	IP 751 is a synthetic orally available analogue of a metabolite of Δ9-tetrahydrocannabinol, acts as a cannabinoid receptor agonist, with Kis of 5.7 nM, 56.1 nM and EC50s of 11.6 nM, 13.4 nM for hCB1 and hCB2 receptors, respectively, and has anti-inflammatory property.
Target	Ki: 5.7 nM (hCB1 receptor), 56.1 nM (hCB2 receptor)EC50: 11.6 nM (hCB1 receptor), 13.4 nM (hCB2 receptor)
Invitro	IP 751 (CT-3; Ajulemic acid) is a synthetic analogue of a metabolite of Δ9-tetrahydrocannabinol, acts as a cannabinoid receptor agonist, with Kis of 5.7 nM, 56.1 nM and EC50s of 11.6 nM, 13.4 nM for hCB1 and hCB2 receptors, respectively, and has anti-inflammatory property[1].
In Vivo	IP 751 (0.1-1 mg/kg, p.o.) causes reversal of hyperalgesia in a dose-dependent manner, with a maximal reversal of 63%, ED50 value of 0.5 mg/kg in a model of neuropathic pain in the rat, and a maximal reversal of 57%, ED50 value of 0.7 mg/kg in a model of inflammatory pain in the rat. However, IP 751 (1, 3, 10 mg/kg, p.o.) shows less potent in the tetrad tests than in the chronic pain models, with ED50s of 5.3 mg/kg, 2.3 mg/kg and 4.3 mg/kg in the rotarod, catalepsy and tail-flick assays, respectively.
Name	Ajulemic acid
CAS	137945-48-3
Formula	C25H36O4
Molar Mass	400.55
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Dyson A, et al. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain. 2005 Jul;116(1-2):129-37.

PeptideDB

Ajulemic acid

CAS: 137945-48-3 F: C25H36O4 W: 400.55